Press Releases

UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clincial Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence

GRENOBLE, France & MINNEAPOLIS, Minnesota (June 25, 2024) — UroMems, a global company developing innovative, implantable mechatronics technology to treat stress urinary incontinence (SUI), today announced it has raised $47 million in its Series C financing, the largest fundraising round to date for the company. The capital will support large-scale U.S. and European pivotal clinical trials of the UroActive™ implant, paving the way for regulatory submission in multiple countries. UroActive is the first smart automated artificial urinary sphincter (AUS) to treat SUI.

Read more.